Inhibition of the Interaction Between the SARS-CoV Spike Protein and Its Cellular Receptor by Anti-histo-blood Group Antibodies

Overview

Journal Glycobiology

Date 2008 Sep 27

PMID 18818423

Citations 210

Authors

Patrice Guillon

Monique Clement

Veronique Sebille

Jean-Gerard Rivain

Chih-Fong Chou

Nathalie Ruvoen-Clouet

Jacques Le Pendu

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic emergent virus which replicates in cells that can express ABH histo-blood group antigens. The heavily glycosylated SARS-CoV spike (S) protein binds to angiotensin-converting enzyme 2 which serves as a cellular receptor. Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection. In this study, we used a cellular model of adhesion to investigate whether natural antibodies of the ABO system could block the S protein and angiotensin-converting enzyme 2 interaction. To this aim, a C-terminally EGFP-tagged S protein was expressed in chinese hamster ovary cells cotransfected with an alpha1,2-fucosyltransferase and an A-transferase in order to coexpress the S glycoprotein ectodomain and the A antigen at the cell surface. We observed that the S protein/angiotensin-converting enzyme 2-dependent adhesion of these cells to an angiotensin-converting enzyme 2 expressing cell line was specifically inhibited by either a monoclonal or human natural anti-A antibodies, indicating that these antibodies may block the interaction between the virus and its receptor, thereby providing protection. In order to more fully appreciate the potential effect of the ABO polymorphism on the epidemiology of SARS, we built a mathematical model of the virus transmission dynamics that takes into account the protective effect of ABO natural antibodies. The model indicated that the ABO polymorphism could contribute to substantially reduce the virus transmission, affecting both the number of infected individuals and the kinetics of the epidemic.

Citing Articles

Immunity and Coagulation in COVID-19.

Avdonin P, Blinova M, Serkova A, Komleva L, Avdonin P Int J Mol Sci. 2024; 25(20).

PMID: 39457048 PMC: 11508857. DOI: 10.3390/ijms252011267.

Lack of association of ABO and RhD blood groups with COVID-19 mortality: A 2-center cross-sectional study in Saudi Arabia.

Halawani A, Alhamoud A, Kabrah S, Al Eissa M, Daowd R, Algarni A Medicine (Baltimore). 2024; 103(37):e39673.

PMID: 39287253 PMC: 11404961. DOI: 10.1097/MD.0000000000039673.

Association Between Rhesus and ABO Blood Group Types and Their Impact on Clinical Outcomes in Critically Ill Patients with COVID-19: A Multi-Center Investigation.

Al Sulaiman K, Aljuhani O, Korayem G, AlFaifi M, Alharthi A, Alshehri A Infect Drug Resist. 2024; 17:3161-3171.

PMID: 39050827 PMC: 11268740. DOI: 10.2147/IDR.S447010.

Relationship between blood group (ABO) and risk of COVID-19 infection in a patient cohort in Tehran, Iran.

Fathollahi A, Bashizadeh Fakhar H, Shaghaghi B Access Microbiol. 2024; 6(6).

PMID: 39045258 PMC: 11261716. DOI: 10.1099/acmi.0.000544.v5.

Blood Group Variations in COVID-19 Convalescent Plasma and Regular Blood Donors: A Comparative Analysis in the Serbian Population.

Grujic J, Budakov-Obradovic Z, Klasnja J, Dinic R, Dolinaj V, Cabezas-Cruz A Microorganisms. 2024; 12(5).

PMID: 38792740 PMC: 11124078. DOI: 10.3390/microorganisms12050915.

References

Ying W, Hao Y, Zhang Y, Peng W, Qin E, Cai Y . Proteomic analysis on structural proteins of Severe Acute Respiratory Syndrome coronavirus. Proteomics. 2004; 4(2):492-504. PMC: 7168022. DOI: 10.1002/pmic.200300676. View

Anderson R, Fraser C, Ghani A, Donnelly C, Riley S, Ferguson N . Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004; 359(1447):1091-105. PMC: 1693389. DOI: 10.1098/rstb.2004.1490. View

. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science. 2004; 303(5664):1666-9. DOI: 10.1126/science.1092002. View

Greenwell P . Blood group antigens: molecules seeking a function?. Glycoconj J. 1997; 14(2):159-73. DOI: 10.1023/a:1018581503164. View

Han D, Lohani M, Cho M . Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol. 2007; 81(21):12029-39. PMC: 2168787. DOI: 10.1128/JVI.00315-07. View

Arendrup M, Hansen J, Clausen H, Nielsen C, Mathiesen L, Nielsen J . Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS. 1991; 5(4):441-4. DOI: 10.1097/00002030-199104000-00014. View

Le Moullac-Vaidye B, Rocher J, Bouhours D, Szpirer C, Le Pendu J . Cloning of a rat gene encoding the histo-blood group A enzyme. Tissue expression of the gene and of the A and B antigens. Eur J Biochem. 2002; 269(16):4040-7. DOI: 10.1046/j.1432-1033.2002.03094.x. View

Mollicone R, Cailleau A, Imberty A, Gane P, Perez S, Oriol R . Recognition of the blood group H type 2 trisaccharide epitope by 28 monoclonal antibodies and three lectins. Glycoconj J. 1996; 13(2):263-71. DOI: 10.1007/BF00731501. View

Chou C, Shen S, Tan Y, Fielding B, Tan T, Fu J . A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J Virol Methods. 2004; 123(1):41-8. PMC: 7112911. DOI: 10.1016/j.jviromet.2004.09.008. View

10.

Preece A, Strahan K, Devitt J, Gustafsson K . Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood. 2002; 99(7):2477-82. DOI: 10.1182/blood.v99.7.2477. View

11.

Stager S, Alexander J, Kirby A, Botto M, van Rooijen N, Smith D . Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med. 2003; 9(10):1287-92. DOI: 10.1038/nm933. View

12.

van der Hoek L . Human coronaviruses: what do they cause?. Antivir Ther. 2007; 12(4 Pt B):651-8. View

13.

Bara J, Gautier R, Le Pendu J, Oriol R . Immunochemical characterization of mucins. Polypeptide (M1) and polysaccharide (A and Leb) antigens. Biochem J. 1988; 254(1):185-93. PMC: 1135055. DOI: 10.1042/bj2540185. View

14.

Durrbach A, Baple E, Preece A, Charpentier B, Gustafsson K . Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation. Eur J Immunol. 2007; 37(5):1254-65. PMC: 7488580. DOI: 10.1002/eji.200636129. View

15.

Seymour R, Allan M, Pomiankowski A, Gustafsson K . Evolution of the human ABO polymorphism by two complementary selective pressures. Proc Biol Sci. 2004; 271(1543):1065-72. PMC: 1691687. DOI: 10.1098/rspb.2004.2674. View

16.

Chakraborti S, Prabakaran P, Xiao X, Dimitrov D . The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J. 2005; 2:73. PMC: 1236967. DOI: 10.1186/1743-422X-2-73. View

17.

Wong S, Li W, Moore M, Choe H, Farzan M . A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2003; 279(5):3197-201. PMC: 7982343. DOI: 10.1074/jbc.C300520200. View

18.

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View

19.

Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H . Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 2007; 75(3):179-87. PMC: 7114093. DOI: 10.1016/j.antiviral.2007.03.003. View

20.

Xiao X, Chakraborti S, Dimitrov A, Gramatikoff K, Dimitrov D . The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun. 2003; 312(4):1159-64. PMC: 7111010. DOI: 10.1016/j.bbrc.2003.11.054. View